Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Whether women with cervical cancer benefit from completion of radical surgery upon intraoperative determination of N1 positivity had been controversial
Identification of the most frequently mutated genes in metastatic renal cell carcinoma
Gene signatures and tumour microenvironments were identified that associate with nivolumab outcomes
Application of the Global Leadership Initiative on Malnutrition criteria
The abundance and heterogeneity of quality of life literature regarding immune checkpoint inhibitors can make patient education difficult
Rheumatic immune-related adverse events resemble classical rheumatic and musculoskeletal diseases with distinct clinical and laboratory characteristics
MK-4830, an antibody targeting the myeloid-specific ILT4 receptor, shows promise in advanced solid tumours
Data from first clinical study of nivolumab in patients with pathogenic edPOLE mutated MMR-proficient tumours
The best response in sarcoma patients treated with pembrolizumab was partial response in the AcSé Pembrolizumab study
Pralsetinib had activity across all RET alterations and regardless of whether the RET mutation was somatic or germline
Sotorasib was active in patients with KRAS p.G12C mutation
Findings from the EPIC-OPC Study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
